 | • レポートコード：MRC23Q36408 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の腱滑膜巨細胞腫治療市場について調査・分析し、世界の腱滑膜巨細胞腫治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（薬物療法、放射線療法、外科手術）、用途別セグメント分析（病院、外科、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Novartis International AG、Roche Holding AG、Bristol Myers Squibb Company、Plexxikon、Daiichi Sankyo Company, Limited、Johnson & Johnson、Bayer AG、Pfizer Inc.、Eli Lilly and Company、Merck & Co.などが含まれています。 世界の腱滑膜巨細胞腫治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、腱滑膜巨細胞腫治療市場規模を推定する際に考慮しました。本レポートは、腱滑膜巨細胞腫治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、腱滑膜巨細胞腫治療に関するビジネス上の意思決定に役立てることを目的としています。 ・腱滑膜巨細胞腫治療市場の概要 - 腱滑膜巨細胞腫治療のタイプ別セグメント - 世界の腱滑膜巨細胞腫治療市場規模：タイプ別分析（薬物療法、放射線療法、外科手術） - 腱滑膜巨細胞腫治療の用途別セグメント - 世界の腱滑膜巨細胞腫治療市場規模：用途別分析（病院、外科、その他） - 世界の腱滑膜巨細胞腫治療市場規模予測（2018年-2029年） ・腱滑膜巨細胞腫治療市場の成長トレンド - 腱滑膜巨細胞腫治療の地域別市場規模（2018年-2029年） - 腱滑膜巨細胞腫治療市場ダイナミクス - 腱滑膜巨細胞腫治療の業界動向 - 腱滑膜巨細胞腫治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：薬物療法、放射線療法、外科手術 - 世界の腱滑膜巨細胞腫治療のタイプ別市場規模（2018年-2023年） - 世界の腱滑膜巨細胞腫治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、外科、その他 - 世界の腱滑膜巨細胞腫治療の用途別市場規模（2018年-2023年） - 世界の腱滑膜巨細胞腫治療の用途別市場規模（2024年-2029年） ・腱滑膜巨細胞腫治療の地域別市場規模 - 北米の腱滑膜巨細胞腫治療市場規模（2018年-2029年） - アメリカの腱滑膜巨細胞腫治療市場規模（2018年-2029年） - ヨーロッパの腱滑膜巨細胞腫治療市場規模（2018年-2029年） - アジア太平洋の腱滑膜巨細胞腫治療市場規模（2018年-2029年） - 中国の腱滑膜巨細胞腫治療市場規模（2018年-2029年） - 日本の腱滑膜巨細胞腫治療市場規模（2018年-2029年） - 韓国の腱滑膜巨細胞腫治療市場規模（2018年-2029年） - インドの腱滑膜巨細胞腫治療市場規模（2018年-2029年） - オーストラリアの腱滑膜巨細胞腫治療市場規模（2018年-2029年） - 中南米の腱滑膜巨細胞腫治療市場規模（2018年-2029年） - 中東・アフリカの腱滑膜巨細胞腫治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Novartis International AG、Roche Holding AG、Bristol Myers Squibb Company、Plexxikon、Daiichi Sankyo Company, Limited、Johnson & Johnson、Bayer AG、Pfizer Inc.、Eli Lilly and Company、Merck & Co. ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Tenosynovial Giant Cell Tumor Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Tenosynovial Giant Cell Tumor Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Tenosynovial Giant Cell Tumor Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Tenosynovial Giant Cell Tumor Treatment in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Tenosynovial Giant Cell Tumor Treatment include Novartis International AG, Roche Holding AG, Bristol Myers Squibb Company, Plexxikon, Daiichi Sankyo Company, Limited, Johnson & Johnson, Bayer AG, Pfizer Inc. and Eli Lilly and Company, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Tenosynovial Giant Cell Tumor Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tenosynovial Giant Cell Tumor Treatment.
The Tenosynovial Giant Cell Tumor Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Tenosynovial Giant Cell Tumor Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tenosynovial Giant Cell Tumor Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Novartis International AG
Roche Holding AG
Bristol Myers Squibb Company
Plexxikon
Daiichi Sankyo Company, Limited
Johnson & Johnson
Bayer AG
Pfizer Inc.
Eli Lilly and Company
Merck & Co.
Segment by Type
Drug Therapy
Radiation Therapy
Surgical Operation
Segment by Application
Hospitals
Surgical clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tenosynovial Giant Cell Tumor Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tenosynovial Giant Cell Tumor Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Drug Therapy
1.2.3 Radiation Therapy
1.2.4 Surgical Operation
1.3 Market by Application
1.3.1 Global Tenosynovial Giant Cell Tumor Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Surgical clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tenosynovial Giant Cell Tumor Treatment Market Perspective (2018-2029)
2.2 Tenosynovial Giant Cell Tumor Treatment Growth Trends by Region
2.2.1 Global Tenosynovial Giant Cell Tumor Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Tenosynovial Giant Cell Tumor Treatment Historic Market Size by Region (2018-2023)
2.2.3 Tenosynovial Giant Cell Tumor Treatment Forecasted Market Size by Region (2024-2029)
2.3 Tenosynovial Giant Cell Tumor Treatment Market Dynamics
2.3.1 Tenosynovial Giant Cell Tumor Treatment Industry Trends
2.3.2 Tenosynovial Giant Cell Tumor Treatment Market Drivers
2.3.3 Tenosynovial Giant Cell Tumor Treatment Market Challenges
2.3.4 Tenosynovial Giant Cell Tumor Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tenosynovial Giant Cell Tumor Treatment Players by Revenue
3.1.1 Global Top Tenosynovial Giant Cell Tumor Treatment Players by Revenue (2018-2023)
3.1.2 Global Tenosynovial Giant Cell Tumor Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Tenosynovial Giant Cell Tumor Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tenosynovial Giant Cell Tumor Treatment Revenue
3.4 Global Tenosynovial Giant Cell Tumor Treatment Market Concentration Ratio
3.4.1 Global Tenosynovial Giant Cell Tumor Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tenosynovial Giant Cell Tumor Treatment Revenue in 2022
3.5 Tenosynovial Giant Cell Tumor Treatment Key Players Head office and Area Served
3.6 Key Players Tenosynovial Giant Cell Tumor Treatment Product Solution and Service
3.7 Date of Enter into Tenosynovial Giant Cell Tumor Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Tenosynovial Giant Cell Tumor Treatment Breakdown Data by Type
4.1 Global Tenosynovial Giant Cell Tumor Treatment Historic Market Size by Type (2018-2023)
4.2 Global Tenosynovial Giant Cell Tumor Treatment Forecasted Market Size by Type (2024-2029)
5 Tenosynovial Giant Cell Tumor Treatment Breakdown Data by Application
5.1 Global Tenosynovial Giant Cell Tumor Treatment Historic Market Size by Application (2018-2023)
5.2 Global Tenosynovial Giant Cell Tumor Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Tenosynovial Giant Cell Tumor Treatment Market Size (2018-2029)
6.2 North America Tenosynovial Giant Cell Tumor Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Tenosynovial Giant Cell Tumor Treatment Market Size by Country (2018-2023)
6.4 North America Tenosynovial Giant Cell Tumor Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tenosynovial Giant Cell Tumor Treatment Market Size (2018-2029)
7.2 Europe Tenosynovial Giant Cell Tumor Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Tenosynovial Giant Cell Tumor Treatment Market Size by Country (2018-2023)
7.4 Europe Tenosynovial Giant Cell Tumor Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tenosynovial Giant Cell Tumor Treatment Market Size (2018-2029)
8.2 Asia-Pacific Tenosynovial Giant Cell Tumor Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Tenosynovial Giant Cell Tumor Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Tenosynovial Giant Cell Tumor Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tenosynovial Giant Cell Tumor Treatment Market Size (2018-2029)
9.2 Latin America Tenosynovial Giant Cell Tumor Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Tenosynovial Giant Cell Tumor Treatment Market Size by Country (2018-2023)
9.4 Latin America Tenosynovial Giant Cell Tumor Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tenosynovial Giant Cell Tumor Treatment Market Size (2018-2029)
10.2 Middle East & Africa Tenosynovial Giant Cell Tumor Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Tenosynovial Giant Cell Tumor Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Tenosynovial Giant Cell Tumor Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis International AG
11.1.1 Novartis International AG Company Detail
11.1.2 Novartis International AG Business Overview
11.1.3 Novartis International AG Tenosynovial Giant Cell Tumor Treatment Introduction
11.1.4 Novartis International AG Revenue in Tenosynovial Giant Cell Tumor Treatment Business (2018-2023)
11.1.5 Novartis International AG Recent Development
11.2 Roche Holding AG
11.2.1 Roche Holding AG Company Detail
11.2.2 Roche Holding AG Business Overview
11.2.3 Roche Holding AG Tenosynovial Giant Cell Tumor Treatment Introduction
11.2.4 Roche Holding AG Revenue in Tenosynovial Giant Cell Tumor Treatment Business (2018-2023)
11.2.5 Roche Holding AG Recent Development
11.3 Bristol Myers Squibb Company
11.3.1 Bristol Myers Squibb Company Company Detail
11.3.2 Bristol Myers Squibb Company Business Overview
11.3.3 Bristol Myers Squibb Company Tenosynovial Giant Cell Tumor Treatment Introduction
11.3.4 Bristol Myers Squibb Company Revenue in Tenosynovial Giant Cell Tumor Treatment Business (2018-2023)
11.3.5 Bristol Myers Squibb Company Recent Development
11.4 Plexxikon
11.4.1 Plexxikon Company Detail
11.4.2 Plexxikon Business Overview
11.4.3 Plexxikon Tenosynovial Giant Cell Tumor Treatment Introduction
11.4.4 Plexxikon Revenue in Tenosynovial Giant Cell Tumor Treatment Business (2018-2023)
11.4.5 Plexxikon Recent Development
11.5 Daiichi Sankyo Company, Limited
11.5.1 Daiichi Sankyo Company, Limited Company Detail
11.5.2 Daiichi Sankyo Company, Limited Business Overview
11.5.3 Daiichi Sankyo Company, Limited Tenosynovial Giant Cell Tumor Treatment Introduction
11.5.4 Daiichi Sankyo Company, Limited Revenue in Tenosynovial Giant Cell Tumor Treatment Business (2018-2023)
11.5.5 Daiichi Sankyo Company, Limited Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Detail
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Tenosynovial Giant Cell Tumor Treatment Introduction
11.6.4 Johnson & Johnson Revenue in Tenosynovial Giant Cell Tumor Treatment Business (2018-2023)
11.6.5 Johnson & Johnson Recent Development
11.7 Bayer AG
11.7.1 Bayer AG Company Detail
11.7.2 Bayer AG Business Overview
11.7.3 Bayer AG Tenosynovial Giant Cell Tumor Treatment Introduction
11.7.4 Bayer AG Revenue in Tenosynovial Giant Cell Tumor Treatment Business (2018-2023)
11.7.5 Bayer AG Recent Development
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Company Detail
11.8.2 Pfizer Inc. Business Overview
11.8.3 Pfizer Inc. Tenosynovial Giant Cell Tumor Treatment Introduction
11.8.4 Pfizer Inc. Revenue in Tenosynovial Giant Cell Tumor Treatment Business (2018-2023)
11.8.5 Pfizer Inc. Recent Development
11.9 Eli Lilly and Company
11.9.1 Eli Lilly and Company Company Detail
11.9.2 Eli Lilly and Company Business Overview
11.9.3 Eli Lilly and Company Tenosynovial Giant Cell Tumor Treatment Introduction
11.9.4 Eli Lilly and Company Revenue in Tenosynovial Giant Cell Tumor Treatment Business (2018-2023)
11.9.5 Eli Lilly and Company Recent Development
11.10 Merck & Co.
11.10.1 Merck & Co. Company Detail
11.10.2 Merck & Co. Business Overview
11.10.3 Merck & Co. Tenosynovial Giant Cell Tumor Treatment Introduction
11.10.4 Merck & Co. Revenue in Tenosynovial Giant Cell Tumor Treatment Business (2018-2023)
11.10.5 Merck & Co. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details